<DOC>
	<DOCNO>NCT01587586</DOCNO>
	<brief_summary>Primary objective : The purpose study determine compare sustain virologic response ( SVR , undetectable HCV RNA Follow week 24 ( FW24 ) ) across treatment group . To determine compare safety tolerability P1101 + Ribavirin across treatment group .</brief_summary>
	<brief_title>Dose Finding Study Pegylated-P-Interferon-alpha-2b ( P1101 ) Treatment-Naive Subjects With HCV Genotype 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adults ≥18 year age ( ≥20 year subject enrolled Taiwan ) ; Confirmed diagnosis chronic hepatitis C ( CHC ) virus genotype 1 infection ; Compensated liver disease : normal elevate ALT/AST , evidence cirrhosis portal hypertension identify ultrasound procedure within 6 month study entry ; Treatment naïve No form chronic liver disease apart chronic hepatitis C infection ; Hematology renal biochemistry definded range ; Be able attend schedule visit comply study procedure ; Be able provide write informed consent . Positive test hepatitis B surface antigen ( HBsAg ) human immunodeficiency virus ( HIV ) screening ; Pregnancy , woman childbearing potential spouse woman , unwillingness inability practice adequate contraception ; Inability comprehend write consent form ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Interferon-alpha</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>